Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: bioengineering – Page 179

The assembly line of the future: Automation, DNA construction, and synthetic biology

This story is brought to you by SynbiCITE, which is accelerating the commercialization of synthetic biology applications. To learn how SynbiCITE is nucleating a sustainable UK economy, visit www.synbicite.com.

Just as Henry Ford’s assembly line revolutionized the automobile industry, synthetic biology is being revolutionized by automated DNA assembly (see SynBioBetaLive! with Opentrons). The key features of an assembly line translate well into the field of synthetic biology – speed, accuracy, reproducibility and validation. Instead of welding chassis together, small robotic arms are lifting delicate plates holding dozens of samples, adding and removing miniscule amounts of fluid.

In 2014, Imperial College London received £2 million to develop a DNA Synthesis and Construction Foundry to operate with SynbiCITE, the UK Innovation and Knowledge Centre for synthetic biology. Speaking at the Foundry’s inception, SynbiCITE co-director Prof. Paul Freemont said, “Standardizing the methods for synthesising DNA is crucial if we are going to scale up efforts to design and create this genetic material. The new DNA Synthesis and Construction Foundry will streamline and automate the ‘writing’ of DNA at an industrial scale so that tens of thousands of designed DNA constructions can be built and tested.”

3D printed biomaterials for bone tissue engineering

When skeletal defects are unable to heal on their own, bone tissue engineering (BTE), a developing field in orthopedics can combine materials science, tissue engineering and regenerative medicine to facilitate bone repair. Materials scientists aim to engineer an ideal biomaterial that can mimic natural bone with cost-effective manufacturing techniques to provide a framework that offers support and biodegrades as new bone forms. Since applications in BTE to restore large bone defects are yet to cross over from the laboratory bench to clinical practice, the field is active with burgeoning research efforts and pioneering technology.

Cost-effective three-dimensional (3D) printing (additive manufacturing) combines economical techniques to create scaffolds with bioinks. Bioengineers at the Pennsylvania State University recently developed a composite ink made of three materials to 3D print porous, -like constructs. The core materials, polycaprolactone (PCL) and poly (D, L-lactic-co-glycolide) acid (PLGA), are two of the most commonly used synthetic, biocompatible biomaterials in BTE. Now published in the Journal of Materials Research, the materials showed biologically favorable interactions in the laboratory, followed by positive outcomes of in an animal model in vivo.

Since bone is a complex structure, Moncal et al. developed a bioink made of biocompatible PCL, PLGA and hydroxyapatite (HAps) particles, combining the properties of bone-like mechanical strength, biodegradation and guided reparative growth (osteoconduction) for assisted natural bone repair. They then engineered a new custom-designed mechanical extrusion system, which was mounted on the Multi-Arm Bioprinter (MABP), previously developed by the same group, to manufacture the 3D constructs.

Journal Club July 2018 — CRISPR may cause unwanted mutations

The July edition of the Journal Club has us taking a look at a recent paper that casts doubt and concern over the use of CRISPR Cas9 for gene editing.

If you like watching these streams and/or would like to participate in future streams, please consider supporting us by becoming a Lifespan Hero: https://www.lifespan.io/hero

The paper we are discussing can be found here: https://www.nature.com/articles/nbt.

Researchers successfully transplant bioengineered lung

A research team at the University of Texas Medical Branch have bioengineered lungs and transplanted them into adult pigs with no medical complication.

In 2014, Joan Nichols and Joaquin Cortiella from The University of Texas Medical Branch at Galveston were the first research team to successfully bioengineer human lungs in a lab. In a paper now available in Science Translational Medicine, they provide details of how their work has progressed from 2014 to the point no complications have occurred in the pigs as part of standard preclinical testing.

“The number of people who have developed severe lung injuries has increased worldwide, while the number of available transplantable organs have decreased,” said Cortiella, professor of pediatric anesthesia. “Our ultimate goal is to eventually provide new options for the many people awaiting a transplant,” said Nichols, professor of internal medicine and associate director of the Galveston National Laboratory at UTMB.

Grow-your-own organs could be here within five years, as scientists prove they work in pigs

Grow-your-own organs could be available for desperately ill patients within five years, after scientists successfully transplanted bioengineered lungs into pigs for the first time.

The team at the University of Texas Medical Branch (UTMB) showed that lab-grown organs were quickly accepted by the animals, and within just two weeks had developed a network of blood vessels.

Previous attempts have failed with several hours of transplantation because the organs did not establish the complicated web of vessels needed for proper oxygen and blood flow.

A Moon For All Mankind

Few in life get to walk on the Moon. Samsung says, do what you can’t. Working with creative agency Iris and engineering experts Mannetron, Framestore proudly joined Samsung’s mission to bring space travel to all, in the approach to the 50th anniversary of the first lunar landing. ‘A Moon For All Mankind’ is the world’s first lunar gravity simulation VR experience, created in collaboration with NASA Johnson Space Center (JSC), using the Samsung Gear VR and a custom-built rig. Having launched under embargo at the 2018 Winter Olympics and at Mobile World Congress, July sees the experience land publicly at Samsung 837, in New York City.

2018 Speakers

I’m excited to share I’ll be speaking/debating at the upcoming #Biohack the Planet 2018 conference in Oakland on Aug 31 & Sept 1. Many interesting biohackers will be there. Tickets are still available and very reasonably priced right now, but they will likely sell out. Hope to see you there! Here’s the speaker list: http://biohacktheplanet.com/2018-speakers/ #transhumanism #biohacker & ticket page: https://www.eventbrite.com/e/biohack-the-planet-2018-ticket…

Bryan Johnson is the founder and CEO of Kernel, OS Fund and Braintree.

In 2016, Bryan invested $100M in Kernel to build advanced neural interfaces to treat disease and dysfunction, illuminate the mechanisms of intelligence, and extend cognition. Kernel is on a mission to dramatically increase our quality of life as healthy lifespans extend. He believes that the future of humanity will be defined by the combination of human and artificial intelligence (HI +AI). In 2014, Bryan invested $100M to start OS Fund which invests in entrepreneurs commercializing breakthrough discoveries in genomics, synthetic biology, artificial intelligence, precision automation, and new materials development. Bryan founded Braintree in 2007, later acquiring Venmo, which he sold to Ebay in 2013 for $800M. He is an outdoor-adventure enthusiast, pilot, and author of a children’s book, Code 7.

Michael Specter is a staff writer at The New Yorker.

Since joining the magazine in 1998, he has written about agricultural biotechnology, the global AIDS epidemic, avian influenza, malaria, the world’s diminishing freshwater resources, synthetic biology, geoengineering, new ways to edit DNA with CRISPR, and the implications of gene drive technology. His profile subjects include: Ingrid Newkirk, the founder of PETA, Dr. Oz, Peter Singer, Vandana Shiva, Miuccia Prada, and Richard Branson. Specter came to The New Yorker from the New York Times, where he had been a roving foreign correspondent based in Rome. From 1995 to 1998, Specter served as co-chief of The Times Moscow bureau. Before working at the Times he was the New York Bureau Chief of The Washington Post.

Continue reading “2018 Speakers” | >

The safety of CRISPR-Cas9 gene editing is being debated

When CRISPR-Cas9 is used to edit genomes, off-target DNA damage is more common than previously thought.

A GREAT deal rides on the accuracy of the gene-editing tool known as CRISPR-Cas9. Since its discovery in 2012 it has become popular for tinkering with genomes of all kinds, thanks to its ability to make editing cheap and easy. Firms such as CRISPR Therapeutics, Intellia Therapeutics and Editas Medicine have been built on the idea that it could be used to develop treatments for human diseases. Editas, based in Cambridge, Massachusetts, announced this year that it would work on five new human medicines over the next five years.

In China the technology is already in clinical use. In Hangzhou Cancer Hospital, for example, CRISPR-Cas9 is being employed to engineer immune-system cells removed from patients with cancer of the oesophagus. The hope is that when the engineered cells are returned to a patient’s body, the editing will have improved their ability to attack tumours. More studies involving human beings are expected in other countries for the treatment of beta-thalassaemia, a blood disorder, and Leber’s congenital amaurosis, a form of blindness. Further ahead, there is hope that CRISPR-Cas9 will help treat diseases such as AIDS, cystic fibrosis, Huntington’s chorea and Duchenne muscular dystrophy.

Get our daily newsletter

Upgrade your inbox and get our Daily Dispatch and Editor’s Picks.